On February 25, 2025, BiomX Inc. entered into a securities purchase agreement to raise approximately $5.5 million through a registered direct offering and private placement, involving the sale of shares and warrants. The company plans to use the proceeds to support a clinical study for a treatment targeting chronic pulmonary infections.